Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: A multitechnique imaging assessment

American Journal of Roentgenology

Volumn 194, Issue 1, 2010, Pages 5-14

  Maksimovic, Olga ^a   Schraml, Christina ^a   Hartmann, Joerg T ^a   Bitzer, Michael ^a   Claussen, Claus D ^a   Pintoffl, Jan ^a   Horger, Marius ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Hepatocellular carcinoma; Multitargeted tyrosine kinase inhibitor; Renal cell carcinoma; Sorafenib; Therapy response monitoring

Indexed keywords

CONTRAST MEDIUM; ECHO CONTRAST MEDIUM; SORAFENIB; THALIDOMIDE;

CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOPPLER FLOWMETRY; DRUG MONITORING; ECHOGRAPHY; HUMAN; IMAGE ANALYSIS; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; TUMOR BLOOD FLOW;

ADRENAL GLAND NEOPLASMS; AGED; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CARCINOMA, RENAL CELL; CONTRAST MEDIA; FEMALE; HUMANS; KIDNEY NEOPLASMS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PHEOCHROMOCYTOMA; PROTEIN KINASE INHIBITORS; PYRIDINES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 74749108466     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2744     Document Type: Review

References (15)

1. Folkman J. Tumor angiogenesis. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, eds. Cancer medicine. Baltimore, MD: Decker, 2000:132-152
2. Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
3. Escudier B, Eisen T, Stadler WM, et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 2007; 356:125-134
4. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. (abstr) Proceedings of the American Society of Clinical Oncology annual meeting. Alexandria, VA: American Society of Clinical Oncology, 2007; 25:240
5. D'Adamo DR, Keohan M, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients with non-GIST sarcomas (CTEP study #7060). (abstr) Proceedings of the American Society of Clinical Oncology annual meeting. Alexandria, VA: American Society of Clinical Oncology, 2007; 25:545
6. Flaherty KT. Sorafenib in renal cell carcinoma. Clin Cancer Res 2007; 13(2 Pt 2):747s-752s
7. Choi H, Charnsangavej C, de Castro Faria S, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR 2004; 183:1619-1628
8. Lassau N, Lamuraglia M, Chami L, et al. Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography. AJR 2006; 187:1267-1273
9. Lamuraglia M, Escudier B, Chami L, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42:2472-2479
10. Elie N, Kaliski A, Péronneau P, et al. Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth. Ultrasound Med Biol 2007; 33:549-560
11. Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13:1029-1035
12. Kabakci N, Igci E, Secil M, et al. Echo contrastenhanced power Doppler ultrasonography for assessment of angiogenesis in renal cell carcinoma. J Ultrasound Med 2005; 24:747-753
13. Miles KA. Measurement of tissue perfusion by dynamic computed tomography. Br J Radiol 1991; 64:409-412
14. Morgan B, Utting JF, Higginson A, et al. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer 2006; 94:1420-1427
15. Atlas SW, DuBois P, Singer MB, et al. Diffusion measurements in intracranial hematomas: implications for MR imaging of acute stroke. AJNR 2000; 21:1190-1194